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The type 2A protein phosphatases in mammalian tissue xtracts are inhibited completely and specifically by 1-2 nM oka- 
daic acid. In contrast, ype l protein phosphatases are hardly affected at these concentrations, complete inhibition requir- 
ing 1 #M okadaic acid. These observations have been exploited to develop an improved procedure for the identification 
and quantitation of type 1, type 2A and type 2C protein phosphatases in tissue xtracts. 
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1. INTRODUCTION 
It is generally accepted that 4 major classes of 
serine/threonine-specific protein phosphatase (PP) 
catalytic subunits are present in the cytoplasmic 
compartment of mammalian cells. These enzymes 
have been subdivided into two groups depending 
on whether they dephosphorylate th  fl-subunit of 
phosphorylase kinase specifically and are inhibited 
by the thermostable proteins inhibitor-1 and 
inhibitor-2 (type 1) or whether they dephospho- 
rylate the a-subunit of phosphorylase kinase 
preferentially and are insensitive to inhibitors 1 and 
2 (type 2). The type 2 phosphatases comprise 3 
distinct groups of enzymes, termed 2A, 2B and 2C, 
which are most simply distinguished by their re- 
quirement for divalent cations. Type 2A phospha- 
tases are active in the absence of divalent cations, 
whereas types 2B and 2C have absolute re- 
quirements for Ca 2+ and Mg 2+, respectively. Type 
1, 2A and 2C have relatively broad and overlapping 
substrate specificities in vitro, while type 2B en- 
zymes display high activity towards relatively few 
substrates (reviewed in [1]). 
Type 1 and type 2A protein phosphatases are the 
only enzymes with significant activity towards 
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glycogen phosphorylase [2]. Type 1 activity in 
tissue extracts has therefore been taken as the pro- 
portion of phosphorylase phosphatase activity that 
can be inactivated by inhibitor 1 or inhibitor 2, and 
type 2A as the activity which is resistant to the in- 
hibitors. However, this procedure might 
underestimate type 1 and overestimate type 2A ac- 
tivity, since complete inhibition of the native forms 
of some type 1 enzymes requires prolonged incuba- 
tion with inhibitors 1 and 2 [3,4], while others may 
be resistant to them [5]. Furthermore, measure- 
ment of type 2C activity in tissue extracts has been 
impossible, because this enzyme accounts for only 
a minor proportion of the phosphatase activity 
towards the substrates that have so far been ex- 
amined [2]. 
In this report a simple procedure is introduced 
for identifying and quantitating type 1, 2A and 2C 
protein phosphatases in mammalian tissue ex- 
tracts, which is based on the use of the tumour pro- 
motor okadaic acid, a potent and specific inhibitor 
of type 1 and type 2A protein phosphatases [6,7]. 
2. EXPERIMENTAL PROCEDURES 
2.1. Materials 
Okadaic acid, a generous gift from Dr Y. Tsukitani, Fujisawa 
Chemical Company, Japan, was dissolved in dimethyl sulphox- 
ide to give a 5 mM solution, and diluted in aqueous buffers 
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before use. The catalytic subunits of type 1 and type 2A protein 
phosphatase [8], type 2C protein phosphatase [9]and inhibitors 
1 and 2 [10] were purified from rabbit skeletal muscle. 
2.2. Tissue extracts 
Rabbit skeletal muscle and brain, rat liver and bovine adrenal 
medulla were homogenized in 2.5 or 3 ml buffer/g wet weight 
as described [2], except for the further inclusion of a proteinase 
inhibitor cocktail [11]. Homogenates of skeletal muscle were 
centrifuged for 45 min at 5000 x g, and those of other tissues 
for 15 min at 16 000 x g. Extracts were prepared from rat 
adipocytes a  in [12]. Supernatants were decanted and used for 
assay of protein phosphatases. Protein concentrations i  the ex- 
tracts determined according to Bradford [13] were: rabbit 
skeletal muscle, 15-20 mg/ml; rabbit brain, 4-5 mg/ml; rat 
liver, 18-22 mg/ml; rat adipocyte, 2.6-3.4 mg/ml; bovine 
adrenal medulla, 12 mg/ml. Glycogen particles were prepared 
from rat liver as in [11]. 
2.3. Preparation of riP-labelled substrates and phosphatase 
assays. 
riP-labelled rabbit skeletal muscle phosphorylase kinase (1.66 
mol phosphate/o~-rt~ unit) [14] and bovine casein (4 nmol 
phosphate/mg [9] were prepared by phosphorylation with cyclic 
AMP-dependent protein kinase, and riP-labelled muscle 
phosphorylase (1.0 mol phosphate/tool subunit) [8] and muscle 
glycogen synthase (1.8 mol phosphate/mol subunit [14]) by 
phosphorylation with phosphorylase kinase and glycogen syn- 
thase kinase 3, respectively. The specific radioactivity of each 
substrate was -~ l0 s dpm/nmol. Type 1 and 2A protein 
phosphatases were assayed in the absence of divalent cations 
and presence of0.1 mM EGTA [8] and type 2C in the presence 
of Mg 2+ [9] using 10/zM phosphorylase, 6/~M riP-casein, 1/~M 
phosphorylase kinase and 1/~M glycogen synthase. One unit of 
activity, U, was that amount which cataiysed the dephospho- 
rylation of 1.0/zmol of substrate inone rain. When inhibitor 1 
or inhibitor 2 were included, diluted extracts were preincubated 
with these proteins for 15 rain prior to initiating the reactions 
with substrate [10]. 
3. RESULTS 
Dephosphorylat ion f glycogen phosphorylase 
by the purified type 1 and type 2A catalytic sub- 
units from rabbit  skeletal muscle was potently in- 
hibited by okadaic acid. However, the concentra- 
t ion required for 50070 inhibit ion (ICso) of the type 
2A enzyme depended on the phosphatase concen- 
trat ion in the assay, ranging from 0.04 nM at 0.03 
mU/ml  to 2.5 nM at 3.0 mU/ml  (fig.l). These 
levels of okadalc acid are similar to the concentra- 
t ion of type 2A phosphatase in the assays, in- 
dicating an extremely strong interaction with the 
tumour  promoter (Kd < 0.01 nM). By contrast, the 
ICs0 for the type 1 catalytic subunit  (12 nM) was 
not significantly affected by increases in 
phosphatase concentration from 0.03 to 3 mU/ml  
(fig. 1). In order to maximise the difference in sen- 
sitivity to okadaic acid between type 1 and type 2A 
phosphatases, tissue extracts were therefore 
assayed at the highest possible di lution (<0.1 
mU/ml  phosphorylase phosphatase). 
To examine whether the native forms of type 1 
and type 2A phosphatases were inhibited by 
okadalc acid with similar potency to the catalytic 
subunits, the effects of this tumour promoter were 
studied in extracts of several mammal ian tissues 
and with several substrates. Provided that the ex- 
tracts were assayed at < 0.1 mU/ml  phosphorylase 
phosphatase, the inhibitor 2 insensitive activity 
measured in the absence of divalent cations (i.e. 
type 2A) was inhibited by okadaic acid with an ICso 
of ~--0.1 nM, essentially complete inhibit ion occur- 
ring at 1-2 nM okadaic acid (fig.2). By contrast, 
activity not blocked by 1 nM okadaic acid (i.e. type 
1), was only inhibited at much higher concentra- 
t ions (ICs0~ 15-20 nM). Similar results were ob- 
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Fig. 1. Influence of enzyme concentration  inhibition of the 
purified catalytic subunits of rabbit skeletal muscle type 1 (PPI) 
and type 2A (PP2A) phosphatases by okadaic acid. Assays were 
carried out with glycogen phosphorylase as substrate. 
Phosphatase concentrations i  the assays were 0.03 (V), 0.1 
(V), 0.3 (O) and 3.0 (e) mU/ml. 
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Fig.2. Effect of okadaic acid on type 1 (PPl) and type 2A 
(PPZA) protein phosphatases in tissue extracts. Assays were 
performed at 600-fold dilutions of the extracts in the presence of 
1 nM okadaic acid (PPl) or after preincubation for 15 min with 
0.2 ,uM inhibitor-2 (PP-2A). Phosphorylase phosphatase 
activity was measured in extracts of bovine adrenal medulla 
(0), rat liver (v, PPl; V, PPZA) and rabbit brain (0); 
phosphorylase kinase phosphatase in an extract of rabbit 
skeletal muscle (x), glycogen synthase phosphatase with the rat 
liver glycogen fraction (0) and casein phosphatase in an extract 
of rabbit brain cortex (m). The experiments were repeated using 
extracts from three different animals with very similar results. 
tained in each tissue examined, and with 
phosphorylase, phosphorylase kinase, glycogen 
synthase or casein as substrates (fig.2). 
The experiments in fig.2 indicated that the native 
forms of type 1 and type 2A phosphatases in 
several mammalian tissues were inhibited by 
okadaic acid with similar potency to the catalytic 
subunits, and that okadaic acid could therefore be 
used as a specific inhibitor of type 2A enzymes. 
Consistent with this conclusion, the effects of 
okadaic acid (2 nM) and inhibitor 2 (0.2 ,uM on 
phosphorylase phosphatase activity in several 
mammalian tissue extracts was additive. Activity 
not inhibited by 2 nM okadaic acid could be sup- 
pressed almost completely by inhibitor 2, while ac- 
tivity not inhibited by inhibitor 2 was blocked by 2 
nM okadaic acid (fig.3). Identical results were ob- 
tained when inhibitor-l (0.1 PM) replaced inhibitor 
2 (not shown). Additive effects of okadaic acid (2 
nM) and inhibitor 1 (0.1 PM), and complete inhibi- 
tion in the presence of both, was also observed 
when phosphorylase kinase or glycogen synthase 
were employed as substrates (not shown). 
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Fig.3. Effect of okadaic acid and inhibitor-2 on phosphorylase 
phosphatase (PhP) activity in tissue extracts. Assays were 
performed in the absence of divalent cations at 600-fold dilution 
(muscle, liver, brain) or 60-fold dilution (adipocyte) in the 
presence of 2 nM okadaic acid (0), after preincubation for 15 
min with 0.2 PM inhibitor-2 (I), 15 min preincubation with 
inhibitor-2 plus okadaic acid (I+ 0), or in the absence of 
okadaic acid and inhibitor-2 (C, control). Control activities 
(undiluted extracts) were: 50 mu/ml (rabbit muscle), 25 mU/ml 
(rat liver), 24 mu/ml (rabbit brain), 2.2 mu/ml (rat adipose). 
The experiments were repeated using extracts from 3 different 
animals with very similar results. 
Type 1 and type 2A protein phosphatases are 
both inhibited completely above 1 PM okadaic acid 
(figs 1,2) suggesting the possibility of quantitating 
type 2C activity in tissue extracts by including high 
levels of this tumour promoter in the assays. In the 
presence of 5 PM okadaic acid, casein phosphatase 
activity in skeletal muscle extracts was completely 
dependent on Mg2+ with an Ao.5 value of = 1.3 
mM (fig.4A). The same result was obtained using 
phosphorylase kinase as a substrate, or other 
tissues such as liver, brain and adipose (not 
shown). Furthermore, the Mg2+ dependent and 
okadaic acid-insensitive activity in muscle extracts 
was specific for the a-subunit of phosphorylase 
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Fig.4. Desphosphorylation of casein (A) and phosphorylase 
kinas¢ (B) by rabbit skeletal muscle xtracts in the presence of 
20 mM Mg 2+ and 5/~M okadalc acid. Assays were performed at 
30-fold (A) or 20-fold (B) dilution of the extracts. In A, 100% 
activity corresponds to the casein phosphatase activity in 
undiluted extracts (1.5 mU/ml). Similar results were obtained 
with extracts prepared from three different animals. In B., the 
phosphorylase kinase substrate contained 0.85 mol 
phosphatase/~'-subunit and 0.81 tool phosphate/ot-subunit, a d 
release of phosphate from the tr (O) and ~ (e) subunits was 
quantitated as in [14]. 
kinase (fig.4B). In contrast, the ~-subunit was 
dephosphorylated selectively in the absence of 
okadaic acid and Mg 2÷ (not shown), as expected 
from the results in fig.3. Other properties of the 
Mg2+-dependent activity, such as its low 
phosphorylase phosphatase activity (not shown) 
were also identical to the type 2C enzymes. 
4. DISCUSSION 
Okadaic acid, a potent umour promoter in two 
stage mouse skin carcinogenesis experiments [15] is 
a specific inhibitor of type 1 and type 2A protein 
phosphatases [6]. PP2B is only inhibited at much 
higher concentrations [6], while PP2C [6], 
pyruvate dehydrogenase phosphatase [7], acid and 
alkaline phosphatases [6], a protein tyrosine 
phosphatase [6] and eight different protein kinases 
tested [7] (including protein kinase C [15]) are unaf- 
fected. Nor does okadaic acid inhibit non-specifi- 
cally a large number of enzymes involved in car- 
bohydrate and lipid metabolism [7]. 
In this paper we have demonstrated a further use 
for okadaic acid in identifying and quantitating 
protein phosphatases in tissue extracts. It is a 
specific inhibitor of type 2A phosphatases at 1-2 
nM, while above 1/~M it inactivates type I as well 
as the type 2A enzymes, allowing measurement of 
type 2C phosphatases in tissue extracts, which has 
previously been impossible. The combined use of 
okadaic acid and inhibitor proteins allows type 1 
and type 2A phosphatases to be quantitated in two 
independent ways. Type 1 phosphatase can be 
taken as the activity which is sensitive to the in- 
hibitor proteins, or as the activity at 5/zM okadaic 
acid subtracted from that measured at 1-2 nM 
okadaic acid. Type 2A phosphatase can be taken as 
the activity which is unaffected by the inhibitor 
proteins, or as the amount which is blocked by 1-2 
nM okadalc acid. Both methods agree to _ 10% in 
skeletal muscle, liver, brain and adipose extracts 
(fig.3), and are most accurate when extracts con- 
tain similar amounts of each phosphatase. If one 
enzyme accounts for 90% or more of the activity, 
accurate quantitation of the other is still difficult 
because large errors are introduced if the inhibitor 
proteins or okadaic acid are only 95% effective. 
Accurate quantitation of type 1, type 2A and type 
2C phosphatases in tissue extracts will facilitate 
studies of the effects of hormones on their ac- 
tivities. 
Two further conclusions may be drawn from this 
study. Firstly, > 90°70 of type 1 phosphatase activi- 
ty in each tissue extract is inhibited by either in- 
hibitor 1 (0.1/~M) or inhibitor 2 (0.2/~M) after 15 
min preincubation, validating the use of these pro- 
teins to estimate type 1 activity. However, an ad- 
vantage of okadaic acid is that it is effective instan- 
taneously and no preincubation is required. 
Secondly, complete inhibition at 1-5/~M okadaic 
acid confirms that type 1 and type 2A phosphatases 
are the only enzymes in tissue extracts with activity 
towards phosphorylase, phosphorylase kinase, 
glycogen synthase and casein, in the absence of 
divalent cations. 
The similar effects of okadaic acid in each mam- 
malian tissue is consistent with recent structural in- 
formation which indicates that the major type 1, 
type 2A and type 2C catalytic subunits are the same 
gene products in skeletal muscle and liver [16-18]. 
Northern blotting indicates that the major mRNAs 
encoding the type 1 and type 2A catalytic subunits 
are 1.6 kb and 2.0 kb, respectively, in a wide varie- 
ty of tissues, including brain [19]. 
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The native type 2A enzymes in which the catalytic 
subunits are complexed to other proteins (i.e. those 
forms present in tissue extracts) are as sensitive to 
okadaic acid as the free catalytic subunit (figs 1 and 
2). This finding is in disagreement with observa- 
tions made by other investigators, who reported 
that the native forms of some type 2A phospha- 
tases were up to lOO-fold less sensitive [6,20]. The 
reason for this discrepancy is unclear, although the 
results presented in fig. 1 show it is critical to com- 
pare the effects of okadaic acid at identical phos- 
phatase concentrations. The purified glycogen 
associated [3] and myofibrillar [21] forms of pro- 
tein phosphatase 1 are also inhibited by okadaic 
acid in a similar manner to the type 1 catalytic 
subunit (not shown). 
The AO.S for Mg2+ of the type 2C protein phos- 
phatase in skeletal muscle extracts was I: 1.3 mM 
with casein as substrate (fig.4). compared to 2.5-3 
mM for the homogeneous 2C2 isoform (not 
shown). This observation suggests that a cofactor 
which increases the affinity of the enzyme for Mg2+ 
may be lost during purification. 
Okadaic acid can enter intact cells, and when 
added to adipocytes or hepatocytes, produces 
marked increases in the phosphorylation states of 
many proteins and alters carbohydrate and lipid 
metabolism in a manner consistent with its action 
as a specific protein phosphatase inhibitor [7]. 
However, although okadaic acid should bind 
preferentially to type 2A phosphatases, it cannot 
be used to determine whether type 1 or type 2A 
phosphatases are the relevant enzymes acting on a 
particular phosphoprotein in vivo. The intra- 
cellular concentrations of these enzymes are both 
0.1-I .O ,uM and similar levels of okadaic acid will 
be required to inhibit both enzymes in intact cells. 
We have recently used the new methodology 
described in this article to identify the protein 
phosphatases acting on acetyl-CoA carboxylase in 
adipose tissue and liver (Cohen, P. and Hardie, 
D.G., unpublished) and tyrosine hydroxylase in 
adrenal medulla and brain 1221. In the following 
paper we demonstrate that these procedures can 
even be applied to yeast [23], suggesting they are 
likely to be useful for the analysis of protein 
phosphatases in all eukaryotic cells. 
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